PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10926382

Comparing inhaled corticosteroids.

G L Colice
View original source ↗Export metadata ↓

Abstract

There are currently available 5 different inhaled corticosteroids, in a variety of different inhalation delivery devices. In the near future there will certainly be more inhaled corticosteroids in newer inhalation delivery devices available in the United States. Tremendous amounts of information will be made available about the relative advantages and disadvantages of these new products. Most of this information will relate to measures of potency, pharmacokinetic profiles, and technical issues about the ease of use. The respiratory care practitioner should be aware that estimating the clinical benefits from the topical anti-inflammatory effects of these newer products will be difficult to determine from this information. Also difficult to understand will be the effects of easier to use inhalation delivery devices on patient adherence to prescribed inhaled corticosteroid dosing regimens. Information from well designed clinical trials should be the basis for comparing presently available and newly developed inhaled corticosteroids.

Explore related subjects

Administration, InhalationAdministration, TopicalAerosolsAnti-Inflammatory AgentsAsthmaClinical Trials as TopicDrug Delivery SystemsGlucocorticoidsHumansPractice Guidelines as TopicComparative StudyJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G L Colice. 2000. Comparing inhaled corticosteroids.. https://pubmed.ncbi.nlm.nih.gov/10926382/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗
PubMed2007

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗